Table 3.
Univariate associations of patient characteristics with time to PSA progression.
| Progression Number (%) | Median Time to Progression (months) |
Log-Rank P-value | |
|---|---|---|---|
| Median age at diagnosis | |||
| <58 years (n=19) | 16(84%) | 28 | 0.99 |
| ≥58 years (n=22) | 17(77%) | 28 | |
| Race | |||
| White (n=35) | 28(80%) | 28 | 0.11 |
| Others (n=6) | 5(83%) | 26 | |
| Gleason score | |||
| ≤6 (n=6) | 4(67%) | 45 | 0.14 |
| 7 (n=24) | 20(83%) | 28 | |
| 8–10 (n=11) | 9(82%) | 26 | |
| Local therapy | |||
| RT only (n=5) | 5(100%) | 28 | 0.67 |
| RP +/− RT (n=36) | 28(78%) | 28 | |
| Prior ADT | |||
| No (n=28) | 22(79%) | 28 | 0.64 |
| Yes (n=13) | 11(85%) | 28 | |
| At Enrollment | |||
| Median age at baseline | |||
| <63 years (n=20) | 17(85%) | 28 | 0.30 |
| ≥63 years (n=21) | 16(76%) | 32 | |
| PSA | |||
| <4.6ng/mL (n=20) | 18(90%) | 28 | 0.30 |
| ≥4.6ng/mL (n=21) | 15(71%) | 28 | |
| PSADT | |||
| <4.4 months (n=20) | 14(70%) | 28 | 0.38 |
| ≥4.4 months (n=21) | 19(90%) | 29 | |
| Testosterone | |||
| <240ng/dL (n=8) | 5(62%) | 24 | 0.76 |
| ≥240ng/dL (n=33) | 28(85%) | 28 | |